We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > FP-025

News List

Foresee announces potential new COVID-19 drug firstwordpharma
July 07, 2021
Foresee Pharmaceuticals' drug FP-025 to treat acute respiratory distress syndrome in COVID-19 patients has been given a nod from an independent data monitoring committee (IDMC) in the US, reported the Taipei Times.
Foresee Pharmaceuticals Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS prnasia
March 29, 2021
Foresee Pharmaceuticals Co., Ltd., today announced the initiation of patient dosing in the Phase 2/3 clinical trial of FP-025, its highly selective oral MMP-12 inhibitor, in adult patients with severe to critical COVID-19 with ...